Details for Patent: 11,701,357
✉ Email this page to a colleague
Which drugs does patent 11,701,357 protect, and when does it expire?
Patent 11,701,357 protects BRUKINSA and is included in two NDAs.
This patent has fourteen patent family members in eleven countries.
Summary for Patent: 11,701,357
| Title: | Treatment of B cell cancers using a combination comprising Btk inhibitors |
| Abstract: | Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof. |
| Inventor(s): | Nan Hu, Lai Wang, Jing Song, Tong Zhang, Kang Li, Lusong Luo, Min Wei, Zhiwei Wang, Yunhang Guo |
| Assignee: | BeOne Medicines I GmbH |
| Application Number: | US16/326,467 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,701,357 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent 11,701,357
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 11,701,357 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY | ⤷ Start Trial | ||||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | TABLET;ORAL | 218785-001 | Jun 10, 2025 | RX | Yes | Yes | 11,701,357 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,701,357
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017313085 | ⤷ Start Trial | |||
| Canada | 3034326 | ⤷ Start Trial | |||
| China | 110087680 | ⤷ Start Trial | |||
| China | 118252927 | ⤷ Start Trial | |||
| Denmark | 3500299 | ⤷ Start Trial | |||
| European Patent Office | 3500299 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
